甲状腺癌患者血浆循环肿瘤DNA含量及BRAF V600E突变联合检测的临床意义

发布时间：2018-05-17 11:32

本文选题：甲状腺癌 + 血浆ctDNA　；参考：《实用医学杂志》2017年14期

【摘要】：目的检测甲状腺癌患者血浆循环肿瘤DNA(ct DNA)的含量及BRAF V600E的突变率,探讨其在临床诊断中的意义。方法利用血液微量基因组DNA提取试剂盒提取16例甲状腺癌患者和59例良性甲状腺结节患者血浆ct DNA,再用荧光定量PCR检测ct DNA含量,以及用PCR法和测序法检测循环BRAF V600E的突变。然后用联合检测分析法分析其临床意义。结果甲状腺癌组ct DNA含量显著高于良性结节组(P0.01)。BRAF V600E突变检测发现甲状腺癌组有7例突变,突变率为43.75%;而良性结节组没有突变。平行联合检测可显著提高灵敏性而系列联合检测特异性更高。结论血浆中ct DNA含量和BRAF V600E突变联合检测有助于甲状腺良恶性结节的鉴别诊断。
[Abstract]:Objective to detect the content of DNA(ct in plasma circulating tumor and the mutation rate of BRAF V600E in patients with thyroid carcinoma, and to explore its significance in clinical diagnosis. Methods Plasma ct DNA was extracted from 16 patients with thyroid carcinoma and 59 patients with benign thyroid nodules by using blood microgenomic DNA extraction kit. The content of ct DNA was detected by fluorescence quantitative PCR, and the mutation of circulating BRAF V600E was detected by PCR and sequencing. Then the clinical significance was analyzed by combined detection method. Results the level of ct DNA in thyroid carcinoma group was significantly higher than that in benign nodule group (P 0.01). BRAF V600E mutation analysis showed that there were 7 cases of thyroid carcinoma with mutation rate of 43.75%, but there was no mutation in benign nodule group. Parallel combined detection can significantly improve the sensitivity and the specificity of series of combined detection is higher. Conclusion the combined detection of ct DNA and BRAF V600E mutation is helpful to the differential diagnosis of benign and malignant thyroid nodules.
【作者单位】：赣南医学院第一附属医院核医学科;赣南医学院第一附属医院耳鼻喉科;赣南医学院第一附属医院CT/MR;
【基金】：赣南医学院校级课题(编号:YB201405) 江西省卫生计生委科技计划(编号:20161105) 江西省教育厅科学技术研究项目(编号:150964)
【分类号】：R736.1

【参考文献】